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ABSTRACT
MODERATE HEAT-ASSISTED GENE ELECTROTRANSFER FOR INTRADERMAL DNA VACCINATION
AND PROTEIN REPLACEMENT THERAPY IN THE SKIN
Chelsea Marie Edelblute
Old Dominion University, 2021
Director: Dr. Richard Heller
Gene electrotransfer (GET) holds great promise for the delivery of therapeutic agents.
The skin serves as an attractive target for GET due to its availability and unique cellular
composition. Protein replacement therapy and DNA vaccination are potential applications for
intradermal GET. The combination of moderate tissue preheating and GET has been shown to
achieve elevated gene expression levels while reducing the necessary applied voltage. In the
current work, we utilized a 16-pin multi-electrode array (MEA) and incorporated nine optical
fibers, connected to an infrared laser, to pre-heat the tissue to 43°C before application of GET.
In a guinea pig model, we found that when the skin was moderately heated, it was possible to
achieve the same expression levels as GET at ambient temperature, with a 23% reduction of
applied voltage or a 50% reduction of pulse number.
Furthermore, moderate tissue pre-heating allowed for delivery to the deep dermis and
muscle, suggesting the potential to reach systemic circulation, a necessary feature for a
successful protein replacement therapy. This approach was repeated using a plasmid encoding
Human Factor IX, the blood clotting factor defective or absent in patients with Hemophilia B.
Elevated Factor IX serum protein levels were detected by ELISA up to 100 days post gene
delivery.

The simple engineering and safety of DNA vaccines make them an attractive candidate
for alternative vaccine types. Here we present moderate heat-assisted GET for the delivery of a
DNA vaccine against Hepatitis B virus (HBV) by way of a plasmid encoding Hepatitis B surface
antigen (pHBsAg) via a prime and prime plus boost vaccination protocol. At 18 weeks post
vaccination, we observed that a high-voltage low-pulse GET condition with moderate heating
(45V 36p +heat) generated antibodies against Hepatitis B surface antigen (HBsAb) at peak
measuring 230-fold over an injection only control. Antibody titers remained robust over the 30week observation period. These data taken together suggest that moderate heat-assisted GET
has the potential to achieve systemic delivery with an intradermal approach, an attractive
feature for development of both a protein replacement therapy as well as a vaccine delivery
platform.
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CHAPTER I
INTRODUCTION
BACKGROUND
Gene electrotransfer
Electrotransfer involves applying an electric field to a cell or tissue to potentiate the
delivery of otherwise impermeable aqueous substances. When the electric field is applied, the
cell membrane becomes temporarily permeable to a greater extent than when in its native
state, a process known as electroporation (1). Extracellular delivery is possible during this quick
and transient period. The temporary pores or imperfections in the cell membrane, which
enhance its permeability, are resolved once the electric field is removed, allowing normal
cellular function to ensue. This approach is referred to as reversible electroporation, where cell
viability is maintained. Conversely, in the case of irreversible electroporation, the intent is
cellular destruction, which has shown efficacy in cancer therapies and tissue ablation (2-5).
In the method of gene electrotransfer (GET), a plasmid encoding a gene of interest is
introduced shortly before application of the electric field through pulse stimulation. The applied
pulses cause a direct electrophoretic effect on the injected plasmid DNA, which promotes its
migration and cellular uptake. Though the exact mechanism of DNA entry into the cell is not
entirely understood, it is clear that the DNA must navigate in some fashion to the nucleus, so it
may be transcribed and translated into protein. Recent work in this area of plasmid DNA entry
suggests the process happens in several key steps. First, there is permeabilization of the plasma
membrane where the DNA is electrophoretically pushed onto and subsequently interacts with
the cell membrane. These DNA-membrane interactions or defects remain for up to 10 minutes
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after the removal of the pulse. In most cases, the DNA will be internalized by endocytosis and is
transported through the cytoplasm. Endosomal escape is the next hurdle for the DNA, after
which it must cross the nuclear envelope to be transcribed and translated. The transgene is
finally expressed and the newly formed proteins are released into the cytoplasm (1,6). Though
this appears to be a treacherous path for the plasmid, current work indicates that cytosolic DNA
sensors, such as DNA-dependent activator of interferon regulatory factors/Z-DNA binding
protein 1, may play an innate role for DNA trafficking following transfection (7).
Nevertheless, early studies demonstrated successful GET in the rat liver and on brain
tumors, indicating enhanced gene delivery efficiency and stability compared to those subjects
receiving injection of DNA alone (8,9). Since those experiments, GET has been demonstrated in
a myriad of tissue types including smooth muscle, skin, skeletal muscle, and even bone.
Likewise, GET has shown efficacy in a number of prophylactic and therapeutic indications
including wound healing, cancer treatment, coronary artery disease, metabolic disorders, and
vaccination (10-17). There have been 98 studies involving electroporation to make it to clinical
trials in the United States, with 41 being currently active. Of those, 36 are for the treatment of
various cancers and 14 involve the testing and delivery of DNA-based vaccines with
electroporation. (clinicaltrials.gov; Keyword: electroporation, search date: March 1, 2021).
Therapeutic utility of heat
Heat has been used therapeutically since antiquity when Hippocrates recorded the
advantages of fever in patients suffering from epilepsy (18). Moreover, in 1927, the Nobel Prize
in Medicine and Physiology was awarded to Julius Wagner-Jauregg for his work on the
therapeutic value of fever in cases of neurosyphilis (19). Likewise, a host-derived fever is one of
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the hallmark immune responses to infection, which has been evolutionarily conserved over
millions of years providing a survival benefit despite its associated metabolic or damaging risks.
Systemic temperature elevation allows for the activation of effector molecules and facilitates
their trafficking throughout the body (20).
In the context of topical therapeutic heat, there are two general categories: deep or
superficial (21,22). Deep heat, achieved with ultrasound or microwaves, reaches a penetration
depth of 3-5 cm. This modality is preferred for treatment of deep-seated conditions such as
Bursitis or Osteoarthritis in the joints (18,22-24). By contrast, superficial heat, such as delivered
by electric heating pads, sodium acetate packs, or patches for minor injuries or sprains, is
applied to achieve a penetration depth of less than 1 cm (24,25). The results of both therapies
are increased blood flow, elasticity of connective tissue, and ultimately pain relief. Though the
use of therapeutic heat is quite commonplace, it is critical that both the temperature and
duration of exposure be monitored to receive the beneficial effects without the damaging
effects (21,25).
There are a number of associated effects of thermal application to consider including
sensation, skin discoloration, cellular processes, and even injury (26-29). Based on these data,
negative effects from thermal injury begin to occur above 44°C (Table 1). Thermal injury is both
temperature and time dependent, where complete transdermal necrosis occurs after just 5
seconds at 63°C while it takes 5000 seconds to induce the same cellular damage at 45°C (25,29).
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Table 1. Summary of thermal injury and associated effects in vivo. Information included in this
table obtained from reference (29).

Sensation

Skin color

Numbness

White

Tissue temp
(°C)
72

Red & White 64-68
Maximum Pain
Severe Pain
Threshold Pain

Bright Red
Light Red

Hot

Flushed

Warm

56-60
45-48
44
36-40

Cellular process

Tissue/cell injury

Protein Coagulation

Irreversible

Thermal inactivation

Possibly reversible

of
tissue contents
Normal

Reversible

None

Metabolism

Skin as a target for GET
The skin is an elaborately organized and highly immunogenic organ. As it is the largest
organ of the body, its sheer size and availability make it an excellent target for GET. It is the
most visible and therefore exposed organ. The skin serves as the effective barrier between the
host and the outside world. Therefore, it functions as the first line of defense against infection
and traumas. Skin acts as an insulator, responsible for regulating fluid loss and absorption as
well as temperature.
The anatomical structure of human skin is made up of three layers from top to bottom:
the epidermis, the dermis, and the hypodermis. The arrangement and thickness of the
epidermal and dermal skin layers depend on its location on the body. In general, the thickest

5

epidermis can be found in thick skin located on the palms and the foot sole measuring
approximately 2 mm (30,31). By contrast, skin found on the arm for example has an
approximate epidermal thickness of 0.8-1 mm. The epidermis is made primarily of
keratinocytes, but also includes melanocytes, Merkel cells, and antigen-presenting dendritic
cells called Langerhans. The epidermis is made up of five bands: the stratum corneum, the
stratum lucidum, the stratum granulosum, the stratum spinosum, and the stratum basale. Cells
are formed at the basal membrane and migrate upwards as they mature. The turnover rate for
the entire epidermal skin layer is approximately 27 days, with the outermost layer of epithelial
cells sloughing off after two weeks (30,31).
The dermis is located beneath the epidermis and provides the circulatory support and
nutrition for the epidermis through communication at the epidermal-dermal junction. The
dermis includes cells such as fibroblasts, monocytes, Langerhans cells, lymphocytes, and
eosinophils, but is mainly comprised of connective tissue (31). Blood and lymph vessels can be
found in the connective tissue matrix of the dermis. These vessels offer support to the
epidermis above and to the hypodermis or subcutaneous tissue below.
The skin is a feasible target for GET. It is accessible, easily monitored, and its highly
immunogenic properties enhance its utility for the delivery of therapeutic agents. Preclinical
studies have used mice, rats, guinea pigs, pigs, and non-human primates as models for skin
research (32-34). The guinea pig serves as a good model for human skin because it has
anatomical similarities. Cellular composition in the dermis including Langerhans cells, dermal
fibroblasts, and macrophages make it a good model. Also, guinea pigs have a comparative
thickness to human skin.
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Two categories of electrodes have been developed for use in skin: penetrating and nonpenetrating. Penetrating electrodes consist of needles arranged in various configurations that
are used to pierce the stratum corneum for pulse delivery. The applied voltage from these
penetrating electrodes is dependent on design, but ranges anywhere from 50-1750V/cm.
Penetrating electrodes have been evaluated as a platform for DNA vaccination demonstrating
adaptive immunity compared to direct injection of plasmid DNA (35).
Non-Penetrating electrodes provide a non-invasive alternative, where the electrode
does not have to be inserted in the skin for pulse application. Caliper and tweezer-type
electrodes were the early configurations of non-penetrating electrodes, which applied pulses in
a single direction. By contrast, four plates oriented in a square pattern could deliver pulses in
multiple directions (36). Though effective for gene electrotransfer, the large gap between
electrodes required high-voltage or high-pulse number to achieve elevated levels of gene
expression. In some cases, the high-voltage or high-pulse number applied induced superficial
skin damage in preclinical testing and presumably pain. Furthermore, the geometry of some of
the configurations provided limited coverage of the target in certain cases.
As a solution to this problem, the multi-electrode array (MEA) was designed providing a
short gap between electrodes, thus effectively reducing the required voltage. This created a
non-penetrating minimally invasive approach to cutaneous gene delivery. The MEA has shown
efficacy in a number of preclinical studies including DNA vaccination against B. anthracis and
Hepatitis B virus, wound healing, and Factor IX protein delivery (37-40).
DNA vaccines
Current vaccines on the pharmaceutical market are comprised of killed whole pathogen,
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pathogen subunits, or live-attenuated viruses. Killed whole pathogen or subunit vaccines confer
their protection primarily through a CD4+ T-cell response and innate immune mechanisms. This
type of response generally does not provide life-long immunity. Several immunization boosters
are thus needed to maintain what is presumed to be adequate protection. Live-attenuated or
weakened viral vaccines are able to induce both the innate and adaptive arms of the immune
response. However, because the virus has been attenuated it inherently is less immunogenic.
Therefore, inducing a more prolonged immunity and requiring less frequent booster
immunizations would be advantageous. Also, the aim to include protection from several
pathogens within one vaccine is appealing, but is difficult to obtain with a live-attenuated
platform. Safety concerns such as reversion to a live state or allergies, which exclude some
population cohorts, remain with current vaccine types. These limitations and others motivate
the development of alternative vaccine platforms.
DNA vaccines provide an attractive alternative. They are non-live and non-replicating
and specifically encode the antigen or antigens of interest. In the early 1990s, DNA vaccinations
were reported to induce antibody responses to viral or bacterial antigens when delivered to
skin or muscle (41-43). In principle, DNA vaccines were able to generate robust immune
responses without the need of a replicating pathogen to purify them. Success in preclinical
studies helped facilitate the translation of DNA vaccines to clinical trials. The first trials
evaluated the efficacy of a DNA vaccine against HIV-1 (44). Criticism of DNA vaccines
questioned the risk of genome integration. There is little evidence of integration observed from
DNA vaccines, and even appears to be lower in risk than that of naturally occurring genetic
mutations (45,46). The list of pathogens successfully targeted by DNA vaccination in clinical
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trials and preclinical studies have included influenza, Human Papilomavirus, Hepatitis B,
Malaria, Zika virus, SARS-CoV, Ebola, and West Nile Virus (47-52). There is even a current
ongoing clinical trial evaluating the use of a DNA vaccine against SARS-CoV-2, the causative
agent of the COVID-19 pandemic. Though safe and well tolerated, results of the completed
studies suggested that injection of plasmid DNA alone was not very immunogenic (47-52).
GET can serve as an adjuvant to enhance the immunogenicity of DNA vaccines. Early
data suggested that humoral responses and cell-mediated immune responses to DNA vaccines
against HBV and HIV gag protein respectively were induced via GET-mediated delivery (53,54).
Since, GET has shown efficacy for stimulating an immune response, additional viral pathogens
such as HIV, HBV, West Nile Virus, and SARS-CoV-2, Human Papillomavirus, and Influenza have
been tested using a GET-delivered DNA vaccine (49,55-62). Taken together, these results
demonstrate the potential of GET to enhance the delivery DNA vaccines as well as their
immunogenicity compared to direct injection.
Primarily, the use of invasive penetrating electrodes has been employed for GETmediated delivery of DNA vaccines. Muscle is the primary site for these applications, as it is
highly vascularized and able to express DNA for a long time compared to other tissues
(15,63,64). Delivery to the muscle can be painful, so the skin has been used as an alternative
site for DNA vaccination using non-penetrating electrodes (38,40,65,66).
Protein replacement therapy
Protein replacement therapy involves the supplementation of or replacement of a
protein which is either deficient or absent due to a genetic abnormality. Protein replacement
has been studied in a wide variety of conditions including blood disorders, metabolic disorders,
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and lysosomal storage disorders (67). Gene therapy has shown promise in the control and
treatment of these disorders.
The most promising data has been shown in the treatment of the blood clotting disorder
Hemophilia (68). Hemophiliacs are missing or deficient in clotting proteins Factor VIII or Factor
IX for Hemophilia A or B respectively. Before the 1960s life expectancy of someone with severe
Hemophilia was less than 20 years old (69). It was at this time that the infusion plasma products
were used to stabilize the disease, however the overall concentration of clotting factors actually
in human-derived plasma was and is still very low. Later that decade, it was found that clotting
factors could be precipitated and pooled from plasma and directly infused. During the HIV/AIDS
epidemic in the 1980s it was found that nearly half of Hemophiliacs had contracted AIDS,
presumably from plasma-derived products. The identification and sequencing of both of these
proteins in the 1990s perpetuated the use of recombinant Factor VIII or Factor IX injections and
fusions, providing an alternative that was not plasma derived (69,70). The current standard of
care is recombinant protein, where prophylactic approach is taken requiring 2-3 infusions each
week. Though effective and life saving, high doses are required to achieve systemic levels, as
are the aforementioned frequent administrations.
Conversely, utilizing gene therapy for this indication can induce sustained protein
expression levels, increasing the time between repeat administrations (71). Viral vectors, such
as recombinant adeno-associated virus (rAAV), have shown some efficacy for the delivery of
Factor VIII and IX proteins (70). Though able to induce high levels of transgene expression, the
use of viral vectors may not be suitable for all patients. A humoral immune response via
neutralizing AAV antibodies is a concern, as approximately 40% of the population has pre-
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existing antibodies against AAV (72). This effectively reduces the protein expression potential in
those patients and eliminates them as potential therapy recipients. Also, a cell-mediated
immune response has been shown in response to the AAV capsid, evidenced by AAV capsidspecific CD8+Tcells (73,74). This not only was shown to cause reduced expression potential, but
also clearance of transduced hepatocytes in liver-directed rAAV delivery (68,75).
Using the skin as an alternative delivery organ for protein replacement therapy is
advantageous. In the case of Hemophilia, where severe bleeding is a real concern, a minimally
invasive approach is crucial. A non-penetrating electrode is thus an attractive platform. Preclinical studies in hairless guinea pig displayed elevated Factor IX protein levels using the MEA
for gene electrotransfer compared to injection of plasmid DNA alone (39). However, protein
levels were much lower than therapeutic levels suggesting this approach would be more suited
for the delivery of low dose protein products such as growth hormone.
RATIONALE AND HYPOTHESIS
The effect of temperature on cells and biological tissues has been well studied, where
an increase in temperature yields an increase in cell permeability (76,77). This membrane
dilation can facilitate the transfer of otherwise impermeable deliverables, such as plasmid DNA,
hormone, or chemotherapeutic drugs to cells or tissues (37,78,79). When the application of
moderate heating and electric field is combined, these effects are more pronounced and
delivery is more efficient (Figure 1). Another consequence of heating is irreversible
electroporation, where the heat sensitizes cancer cells to the applied electric field, thus making
a more effective treatment (3,4).
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Figure 1. Schematic theoretical representation of moderate heat-assisted GET. GET is
considered a nonthermal process requiring a high voltage pulse to deliver plasmid DNA through
transient perturbations in the cell membrane. The use of moderate heat reduces the required
voltage for GET. The membrane becomes more fluid under moderate heat allowing for delivery
at the lower applied voltage.

In the current work, we present a platform for reversible electroporation, where cell
viability is maintained. We present utility of the minimally invasive non-penetrating 16-pin MEA
with the incorporation of an infrared laser for moderate heating of the target tissue. We heat
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the skin to a moderate temperature of 43°C for a total of 30 seconds and maintain an elevated
temperature for an additional 20 seconds after the exogenous heat source is removed. At this
temperature, 41-43°C, the skin is temporarily warm and normal metabolism still proceeds. An
infrared laser was chosen as the heating source in this case due to its speed and precision at
which the target temperature could be reached.
In our previous work, a four pin MEA was utilized with a centrally located infrared laser
shining out of a single optical fiber for moderate heating. This worked well as a proof of
principle, but the gap between the electrodes and laser beam path, suggested moderate
heating coverage of the target tissue could be improved (78). In addition, an applied voltage of
50V was required for thermally-assisted GET. By utilizing a 16-pin MEA we are able to reduce
the electrode gap due to its geometry and thereby reduce the necessary applied voltage for
gene delivery. Also, the 2 mm gap between electrodes left enough spacing to include nine
optical fibers. In theory, this allows for greater coverage of the target tissue than when using a
single fiber. Combined, the use of moderate heating and a shorter electrode gap suggested the
potential to reduce electrotransfer conditions even further all while maintaining or enhancing
gene expression.
The current design is novel compared to our previous work, with the infrared laser split
equally among nine interspaced optical fibers. We hypothesize that this configuration will yield
more uniform heating compared to our previous design and allow for reductions in either
necessary applied voltage and/or pulse number. We tested this device for the delivery of
reporter genes to assess both the kinetics and distribution of gene expression following
moderate heat-assisted GET. We hypothesize that the addition of moderate heating
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incorporated into the 16-pin MEA would yield higher expression levels compared to its
unheated counterpart and that moderate heating would facilitate applied voltage reduction.
A minimally invasive platform is advantageous for non-life-threatening applications such
as vaccination. Furthermore, an approach that generates a robust systemic response will
require less frequent booster immunizations. To determine the potential of utilizing moderate
heat-assisted GET for DNA vaccination, a DNA vaccination protocol against HBV was carried out.
We have previously shown efficacy in utilizing the MEA for GET of a plasmid encoding Hepatitis
B surface antigen to achieve detectable neutralizing anti-HBs. We sought to improve upon that
ambient platform with our moderately heated platform. High-voltage low-pulse number and
low-voltage high-pulse number conditions were mediated with the addition of moderate
heating. We hypothesize the addition of moderate heating will result in elevated antibodies to
HBsAg detected in serum compared to its unheated counterpart.
Lastly, we sought to evaluate moderate heat-assisted GET for the cutaneous delivery of
human Factor IX in an in vivo guinea pig model. Like vaccination, a minimally invasive platform
is ideal for Factor IX replacement therapies as frequent administrations are typically required.
The aim would be to create a less painful and less frequent treatment plan. We previously
demonstrated delivery of Factor IX in hairless guinea pigs using the MEA. Here we expand upon
this work with the addition of heat, as those early studies indicated that the amount of Factor
IX to reach circulation was quite low. We hypothesize that the addition of moderate heating will
facilitate the delivery of Factor IX via intradermal GET to reach systemic levels rather than just
local.
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CHAPTER II
MODERATE HEAT-ASSISTED GET DEVICE
ELECTRODE ASSEMBLY AND MODERATE HEATING PARAMETERS
GET device
Moderate heating and GET delivery were incased in a single novel device for ease of use
in a streamlined approach. Providing one device for this application facilitates its translation for
future use in a clinical setting. The design of the Multi-electrode Array (MEA) GET delivery
device has been previously described (36,80,81). The electrode included 16 spring-loaded goldplated round-tipped pins arranged in a 4x4 square pattern 2-mm apart from one another.
GET delivery parameters
Each pair of conductive electrodes was programmed to administer either a train of two
or four pulses. In the current work, these pulse trains were administered as four pulses 18
times for a total of 72 pulses or two pulses administered 18 times for a total of 36 pulses
depending on desired GET conditions. The applied voltages used for this study were either 35 or
45V between two conductive pins, where each pulse had a duration of 150 ms with a 150 ms
delay between pulses. Electrotransfer pulsing was performed using the UltraVolt Model: Rack2-500-00230 (UltraVolt, Inc. Ronkonkoma, NY, USA).
Infrared laser system for moderate heating
An infrared radiation emitter was integrated into the design of the MEA GET applicator.
Though the moderate heating and GET delivery was incased in a single handheld device,
moderate heating was always applied before GET in these experiments, as a way to pre-heat
the target tissue. Moderate heating was applied to maintain a surface temperature of the

15

treatment site tissue at 43°C. The heating system consisted of a 980 nm wavelength infrared
laser (Lasermate Group Inc, Walnut, California), an optical fiber that delivers the infrared
radiation laser light to the skin, and an emission splitter. The infrared laser emitter consisted of
an optical fiber whose beam was split equally among nine individual optical fibers that utilized
four separate splitter boxes (Figure 2). The primary optical fiber was connected directly to a
three-way splitter box, which had three fibers each connected to another three-way splitter
box. Each connection to the splitter boxes had a shutter than was open or closed manually to
control the laser beam.
The nine optical fibers are positioned equidistant and centrally between 16 0.5mm goldplated round tipped pins of the MEA each spaced 2mm apart, creating a combined 6 by 6 mm
moderate heating electrode array (Figure 3). As previously shown, the small size and dielectric
material of the optical fiber can be integrated into a GET delivery system without causing
electrical interference [69].
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Figure 2. Infrared laser heating system for moderate heat-assisted GET. The main optical fiber
for moderate heating connects to a primary three-way splitter box. Three secondary splitter
boxes are then connected each by via three separate optical fibers to the primary three-way
splitter box (orange wires). Each of the three secondary splitter boxes directs the laser beam
through three optical fibers all connected to the main optical fiber. The controlling the opening
and shutting of nine individual fibers is performed manually by nine individual shutters.
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Figure 3. Moderate heat-assisted GET device. (A) Moderate heating is performed by an infrared
laser split through nine equally spaced optical fibers (red circles). GET is applied from springloaded pins placed in contact with skin target (blue circles). (B) In reality, the 16-pin MEA with
evenly interspersed nine optical fibers utilized for moderate heat-assisted all encased within a
non-conductive Teflon cap. Blank pin at left of image (*) indicates a place marker for
maintaining uniformity in placement of the electrode.

MODERATE HEATING PARAMETERS EX VIVO
Ex vivo pig skin model
Porcine skin was acquired post-mortem from an existing IACUC approved protocol with
proper permissions. Skin was removed from the flank and void of excess hair. The skin sections
were then embedded in Optimal Cutting Temperature compound and frozen at −80 °C. To
obtain serial sections, individual pieces were mounted en face and cryosectioned serially
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starting from the outermost epidermal side. A 200µm serial depth pattern was performed on
the cryostat. This allowed us to profile heating at depths of 200µm, 400µm, and 600µm.
All laser heating calibrations were performed by placing the electrode casing with
integrated laser in a micromanipulator and aligning the laser with a resistance temperature
detector (RTD) thermocouple (Figure 4). Once the laser was aligned, the location was fixed. This
set-up reduced the error that could be attributed to any unsteadiness in the holding position.
The laser power supply was set to 3 amperes for these experiments yielding an ideal fast risetime. Serial pig skin sections were carefully stacked with outermost epidermal layer on top. A
RTD thermocouple was sandwiched in-between each layer in subsequent experiments in order
to record the temperature at specific depths before, during, and after laser heating.
Temperature distribution at sequential depths of 200µm, 400µm, and 600µm were
recorded. Temperature measurements were taken at a rate of 5 reads per second, with the
resulting temperature value being an average of these 5 readings. Baseline temperature was
measured prior to turning on the laser for heating. For the outermost skin depth, 200µm, the
laser was turned off once the temperature at the RTD thermocouple reached 43°C and the time
for temperature decay was measured. For subsequent depths, the thermocouple was moved to
the next deepest layer and the laser was turned off at the same time that the first depth
reached 43°C. Likewise, the temperature decay was followed. At each sequential depth, the
entire stack was shifted slightly, ensuring the same region was not directly heated each time.
Baseline temperature of the pig skin sections were recorded as 21.6 ± 0.3°C at 200µm,
21.9 ± 0.6°C at 400µm, and 21.3 ± 0.5°C at 600µm. At a 200µm depth, the laser was able to heat
pig skin to 43°C in 6 seconds after turning on the laser and setting the power to 3 amperes. At
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this same time point the temperatures at 400µm and 600µm were 36.0 ± 4.4°C and 34.7 ± 2.6°C
respectively. The temperature gradually declined and returned to baseline after 35 seconds
(Figure 5).

Figure 4. Laser heating calibration set-up. A micromanipulator was used to obtain steady
measurements of laser heating in an ex vivo model. Serial pig skin sections were stacked on top
of an RTD thermocouple that was used to obtain temperature measurements. This set-up was
repeated for all tested samples.
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Figure 5. Depth of laser heating in an ex vivo porcine skin model. Frozen pig skin was sectioned
serially at 200μm depths on an upright cryostat. Serial pig skin sections were stacked with
outermost epidermal face on top. A thermocouple was placed at subsequent 200μm depths inbetween each graft to obtain temporal temperature measurements following laser heat
application: 200μm, 400μm, and 600μm. All experiments were performed with the laser
attached to a micromanipulator to prevent excess movement and ensure alignment for the
duration of the recorded time. Temperature measurements were taken at 5-second intervals
for a total of 35 seconds. A target temperature of 43°C was reached before turning off the laser,
after which temperature decay was recorded. Data represent average temperature (°C), n=5
individual stacks.
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Recellularized dermis
Recellularization of human dermal constructs was performed using an established
protocol (82). Briefly, DermACELL® (LifeNet Health, Virginia Beach, VA) grafts were washed in
DPBS and cut into 12mm disks using a biopsy punch, then washed twice with complete DMEM
media. Human primary dermal fibroblasts (ATCC, Manassas, VA) were maintained in culture
with DMEM, 10% fetal bovine serum, 1% Penicillin/Streptomycin at 37°C and 5% CO2. Culture
medium was replaced every 2-3 days. HaCaT cells were maintained in culture using both the
same media formulations and growth conditions as the fibroblasts.
Fibroblasts were seeded at a density of 1x106 cells/disk on the reticular face of the
dermis. After fibroblast attachment, the constructs were transferred to fresh wells. Fibroblasts
were maintained on the dermis for one week, allowing for cell infiltration throughout the
matrix. On the papillary face, HaCaT cells were seeded at a density of 1.5x105 cells/disk. HaCaT
cells attached overnight, and the grafts were moved to the upper chamber of Transwell
Permeable Supports (Corning Incorporated, Life Sciences, Tewksbury, MA). The bottom well
was filled with fresh media, while the top well was left void of any media, effectively lifting the
grafts to an air-liquid interface (Figure 6). This action allowed for epithelial cell stratification.
Recellularized dermis was cultured for 3 weeks with daily media changes before applying
moderate heating.
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Figure 6. Diagram of air-liquid interface culture of recellularized dermis. Dermal constructs
were cultured at an air-liquid interface to encourage stratification of epithelial cells. Complete
DMEM media in the bottom well was replaced daily and excess moisture removed from the top
of the Transwell. Figure reproduced with permissions from reference (82).

Moderate heat calibration in a 3D human skin model
Before advancing to an in vivo model, the novel moderate heating set-up was assessed
in recellularized human dermal constructs. The recellularized human skin grafts were 3.5 weeks
old in culture when used for this experiment. The grafts were carefully removed from their
transwells using forceps, so as not to disrupt the newly formed epithelium. The graft was
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dabbed dry using sterile gauze to remove excess fluid from both sides of the graft. The graft
was injected intradermally with 50µL of 0.9% physiological saline in the center of the graft. The
graft was then placed, with the reticular side facing up, directly on top of the RTD
thermocouple, which had been pre-aligned with the laser fiber at a distance of 1.5cm from the
graft. Temperature measurements were also taken every 5 seconds. Baseline temperature was
measured prior to turning on the laser for heating. The laser was turned off once the
temperature reached 43°C, and the time for temperature decay was measured.
After heating, the recellularized human skin grafts were fixed in 4% PFA. For storing, the
samples were placed in a gradient of Optimal Cutting Temperature (OCT) compound overnight
on a rotator ensuring proper fixation. The grafts were then frozen in OCT and stored at -80°C
until sectioned. Grafts were then sectioned on a cryostat to determine the thickness of each
graft. A hematoxylin and eosin (H&E) staining protocol was performed to visualize the graft
sections (Figure 7).
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Figure 7. H&E staining of recellularized dermal grafts. An H&E staining was performed on
recellularized dermal grafts following infrared laser heating. Samples were fixed in 4% PFA,
placed in OCT, and frozen until sectioning. Grafts were sectioned on an upright cryostat. All
micrographs were taken on a Leica systems inverted microscope. Scale bar = 500μm,
magnification = 40x.

Using the measuring tool in IMAGEJ, a scale was set for each image using the existing
scale bar. Three separate regions of the stained tissue were measured from epidermal to
dermal face and averaged to obtain average graft thickness (Table 2).

25

Table 2. Recellularized dermal graft thickness. Recellularized dermal constructs cultured for
three weeks were fixed and stained using an H&E protocol. Micrographs were taken on a Leica
systems inverted microscope and imported into IMAGE J for measurements. Three separate
regions on the graft were identified, measured, and averaged to determine graft thickness
(μm). The standard deviation (stdev) between the three measurements were recorded.
Recellularized dermis thickness (μm)
Sample ID

Measure 1

1

416.56

2

Measure 2

Measure 3

Average

Stdev

417.83

447.13

427.17

17.29

355.85

363.64

388.31

369.27

16.95

3

348.43

357.23

373.59

359.75

12.77

4

570.97

706.45

619.36

632.26

68.66

5

575.96

699.43

560.14

611.84

76.26

6

525.79

518.25

505.66

516.57

10.17

Baseline temperature of the recellularized dermal skin grafts was recorded as 18.3 ±
0.1°C, with the skin graft placed on top of the RTD thermocouple (Figure 8). It took 20 seconds
for the skin graft to be heated to 42.0 ± 1.2°C. The depth of this temperature reading varied
depending on the thickness of the graft.
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Figure 8. Temporal heating of recellularized dermal grafts. An infrared laser was used to heat
the 3D human skin model to 43°C. Temperature measurements were taken via a thermocouple
placed underneath the graft aligned with the output laser beam. Temperature measurements
were recorded in 5-second intervals. The laser heat source was turned off once the underside
of the graft reached 43°C. After which, the temperature decay was monitored until returning to
baseline. The data represent the mean temperature (°C) ± standard error of the mean (SEM),
n=6 individual grafts.
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MODERATE HEATING PARAMETERS IN VIVO
Animals
The in vivo animal model used for this study was the guinea pig, as guinea pig skin
shares similarities in thickness and composition with human skin. Animals used for this study
were 8-10-week-old Female Hartley guinea pigs weighing approximately 300-350g at the time
of treatment. The animals were housed at the Old Dominion University animal facility and
procedures approved by the Old Dominion Institutional Animal Care and Use Committee
approval #17-022. All animal subjects were quarantined for a minimum of 7 days following
arrival and prior to the conduction of any procedures.
Moderate heat application and duration
All animals were anesthetized during moderate heating. Anesthesia was performed by
placing the animals into an induction chamber infused with 3-4% isofluorane and 96-97%
oxygen gas. After animals were sufficiently anesthetized, they were fitted with a standard
rodent mask supplied with 3% isofluorane and oxygen to maintain a surgical plane of
anesthesia for the duration of the procedure. Animals were placed on a heating pad to ensure
thermoregulation during the entire procedure. Animals were then shaven and washed with
mild soap (Dial) and water in an outward circular motion to remove any loose hair or an
overabundance of oil.
Prior to utilizing the addition of moderate heat in combination with the administration
of GET, the time needed to raise the temperature of the dermis using the infrared laser in this
novel configuration was determined. Temperature measurements were accomplished by
inserting an 18G needle intradermally into either the pre-shaven left or right flank then
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carefully replacing the needle with a K-type thermocouple temperature probe (Omega,
Stamford, CT, USA), which was guided through the needle shaft and out the bevel. Temperature
was recorded via a digital output.
Baseline temperature in an anesthetized guinea pig kept under thermoregulation via a
heating pad was determined to be 35°C. For moderate heat application, the electrode was
placed with the spring-loaded GET electrode pins in contact perpendicularly with the skin,
leaving a fixed distance of 1 cm between the optical fibers and the skin target. Gentle pressure
was applied to ensure uniform contact. With the thermocouple in place, temperature
measurements were then obtained during the application of moderate heat. Safety precautions
such as eyewear and barriers were in place during all laser operations.
We assessed the heating capabilities of three, six, and nine operating optical fiber
configurations to determine which provided the most uniform, fast, and stable intradermal
heating. The target intradermal temperature for this experiment was 43°C, which was
previously determined to be the ideal moderate heating temperature for GET both in vitro and
in vivo (79,37). An intradermal temperature of 43°C was achieved after operating the infrared
laser across all nine optical fibers arranged in three rows for 30 seconds at 8 amps. This
elevated temperature was maintained for approximately 30 seconds, thus allowing for the
maximal 20-second GET pulse protocol to be completed while the tissue remained moderately
heated (Figure 9). These heating parameters and duration were in-line with previously reported
results from our group utilizing the same infrared laser though here we present an updated
applicator design (78). The temperature remained elevated above 41°C for 20 seconds. There
was no significant difference between all tested heating configurations: three, six, or nine
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optical fibers. All moderate heating configurations were repeated at three individual sites. The
data reported represent the average temperature (°C) ± the standard deviation.

Figure 9. Intradermal skin temperature during moderate heating. In vivo intradermal
temperature measured by a K-type thermocouple. Baseline temperature was recorded prior to
each heating iteration- 3, 6, or 9 fibers. Moderate heating was applied via infrared laser
positioned 1 cm away from the skin target. A target temperature of 43°C was attempted for
each heating condition, after which the exogenous heating source was manually turned off and
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intradermal temperature decay was measured. Temperature measurements were recorded at
5-second intervals for a total of 60 seconds. Average temperature is reported in degrees C per
second ± stdev, n=3 sites per group.
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CHAPTER III
DELIVERY OF REPORTER GENES USING MODERATE HEAT-ASSISTED GET
INTRODUCTION
Before advancing to a therapeutic model, the use of reporter genes is important for
determining both the kinetics of expression and the distribution within the tissue following
moderate heat-assisted GET. Our previous work demonstrated that expression could be
enhanced and/or the applied voltage reduced by preheating the tissue prior to pulse
administration. In the current study, we utilized our 16-pin MEA and incorporated nine optical
fibers, connected to an infrared laser, between each set of 4 electrodes to heat the tissue to
43°C. For proof of principle, a guinea pig model was used to test delivery of reporter genes. The
two reporter genes used in this work were luciferase and a DDK protein tag each encoded on a
plasmid with a gWiz backbone and pCMV promoter.
While increased temperature can enhance delivery when used together with GET, it is
also important to moderate the applied heat so as not to cause tissue damage. We previously
established that the optimal intradermal temperature for enhancing GET was 43°C. It takes
several minutes to cause a burn at 43°C, our pulse protocol is far under this threshold. We
developed a moderate heating protocol using an infrared laser that demonstrated a 30 second
preheating duration was sufficient for sustained temperature during the proceeding pulsing
protocol. Tissue integrity following moderate heat-assisted GET was evaluated through
histological analysis using an H&E staining protocol. Furthermore, a dosing study was carried
out where both volume and concentration of plasmid DNA were varied to determine the
optimal injection for moderate heat-assisted GET for achieving the greatest coverage and
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overall expression levels. The synergy between moderate heating and electroporation allows
for the reduction of both the necessary applied voltage and pulse number. These reductions
have the potential to create an application that is less painful for the recipient and easier to
apply for the clinician.
MATERIALS AND METHODS
Animals
Animals used for this study were 8-10-week-old Female Hartley guinea pigs weighing
approximately 300-350g at the time of treatment. The animals were housed at the Old
Dominion University animal facility and procedures approved by the Old Dominion Institutional
Animal Care and Use Committee approval #17-022. All animal subjects were quarantined for a
minimum of 7 days following arrival and prior to the conduction of any procedures.
Animal euthanasia was performed at the conclusion of each respective observation
period. Euthanasia was carried out by first anesthetizing the animals in a chamber filled with 4%
isoflurane combined with 96% oxygen. After 15 minutes, the animals were transferred to a
separate chamber and euthanized by exposure to carbon dioxide for 15 minutes. Compressed
gas was used as the carbon dioxide source. The chamber was not pre-filled, but slowly filled,
and cleaned and dried between animal groups. A bilateral thoracotomy was performed to
confirm euthanasia. This secondary euthanasia procedure was only performed after cessation
of respiratory and cardiovascular movements was confirmed. Euthanasia procedures were
approved by the IACUC at ODU and were followed in accordance with those guidelines.
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Plasmids
Endotoxin-free plasmid preparations at 2mg/ml in 0.9% sterile injectable saline of
gWizLuc, encoding firefly luciferase, and gWizLuc-myc-DDK, encoding the oncogene myc and a
DDK protein tag, were commercially prepared for this study (Aldevron, Fargo, ND). Both
plasmids have a gWiz backbone and a CMV promoter.
Infrared laser heat application
Animals were anesthetized with O2 containing 2.5-3.0% isoflurane. Prior to treatment
both flanks were shaved and washed with mild soap and water to remove loose hair and
cleanse the skin of any abundance of oil. Moderate heating via a Class IV Laser power supply
(LaserMate Group, Inc) via a laser optic fiber (Model: M79L005 Thor Labs Inc.) was applied
immediately following a 50μL 2mg/mL intradermal injection of plasmid DNA to the pre-washed
and shaven flank skin for a total duration of 30 seconds, after which the laser was switched off.
All safety precautions were adhered to while the laser was in operation, including eye
protection and barriers. All staff were trained and received operation approval via the Radiation
& Laser Safety Program at Old Dominion University prior to the conduction of any experiments.
Reporter gene delivery
Animals were anesthetized with O2 containing 2.5-3.0% isoflurane. Animals were preshaven and washed with mild soap and water to remove any loose hair or an overabundance of
oil. A 100μg intradermal injection of plasmid DNA was delivered to the flank. Injection sites
were marked to ensure accuracy of data collection. The electrode array was immediately
positioned over the injection area with or without exogenous moderate heating. For these
studies both 2 and 4 rounds of 18, 150ms pulses were delivered, yielding a total of 36 and 72
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pulses respectively. In addition, applied voltages of 35V and 45V were assessed. Gene
expression levels were measured for all conditions by in vivo bioluminescent imaging or
fluorescent imaging.
In vivo bioluminescent imaging and kinetic expression analysis
On days 2, 5, 7, 9, and 14, animals were anesthetized with O2 containing 2.5-3.0%
isoflurane followed by a single subcutaneous injection of D-luciferin (Gold Biotechnology, St.
Louis, MO) at 150mg/kg administered at the neck scruff. The animals were confined in an
anesthesia chamber for eight minutes then transferred to the IVIS® Spectrum (Perkin Elmer,
Akron, OH), imaging chamber under constant anesthesia. Regions of interest (ROI) were
selected on the image to encompass the entirety of each injection site independently and
compared to untreated control ROIs. After background correction, bioluminescence results
were represented as average total flux in photons/sec (p/s).
Immunofluorescence staining and distribution expression analysis
The

localization

of

gene

delivery

within

the

skin

was

determined

by

immunofluorescence staining for the DDK tag protein. Skin samples were collected 48 hours
post gene transfer, fixed in 4% paraformaldehyde, paraffin embedded, and sectioned to sixmicron thickness by IDEXX Laboratories, Inc. (Westbrook, Maine). Hematoxylin and eosin
staining was also performed on serial sections by IDEXX Laboratories. Unstained sections were
deparaffinized using CitriSolv, and rehydrated in gradient alcohol (100, 95, 75, 50, and 25%).
Antigen retrieval was performed in citric acid (pH 6). Cell permeabilization was performed for
20 min in 0.25% Triton X-100 in phosphate buffered saline (PBS). Blocking was performed with
4% bovine serum albumin in phosphate buffered saline with 0.01% Tween 20 (PBST) for 1 h at
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room temperature. Sections were then stained for immunoreactivity with DDK-tag protein with
a mouse monoclonal anti-DDK antibody (TA50011–1, OriGene, Rockville, MD) diluted 1:200 in
blocking buffer overnight at 4 °C. Samples were then labeled with an AlexaFluor488 conjugated
goat anti-mouse IgG secondary antibody (ThermoFisher Scientific, Grand Island NY).
All samples were washed with PBST five times for three minutes each time on a shaker
between antibody applications. Negative control samples were treated with secondary
antibody only, without the primary antibody. All staining procedures were performed in the
dark to prevent photobleaching. Samples were counterstained with DAPI for cell nuclei
identification

and

mounted

with

VECTASHIELD® HardSet™ mounting

medium

(Vector

Laboratories, Burlingame, CA) after which they were set at room temperature in the dark
overnight. After the coverslips had set, the samples were stored at −20 °C until imaging.
Plasmid dosing for moderate heat-assisted GET
Volume and concentration of plasmid DNA was assessed to determine the appropriate
dose to achieve the highest expression level with minimum adverse tissue effects. For this
experiment we used a plasmid encoding the reporter gene luciferase. Anesthesia was
performed by placing the animals in an induction chamber infused with 3-4% isofluorane and
96-97% oxygen gas. After animals were sufficiently anesthetized, they were fitted with a
standard rodent mask supplied with 3% isofluorane and oxygen to maintain a surgical plane of
anesthesia. Animals were placed on a heating pad to ensure thermoregulation during the entire
procedure. Animals were shaven and washed with mild soap (Dial) and water in an outward
circular motion to remove any loose hair or an overabundance of oil.
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Injection sites were marked to ensure accuracy of data collection. gWizLuc plasmid
doses included volumes of 50 or 100μL at 0.5, 1, or 2mg/mL. The electrode array was
immediately positioned over the injection area. When applicable, moderate heating was always
applied after injection, but before GET. The four experimental groups included injection only
(IO), injection of pDNA followed by 72 pulses at 45V (45V 72 p), injection of pDNA followed by
72 pulses at 35V with moderate heat (35V 72p + heat), and injection of pDNA followed by 36
pulses at 45V with moderate heat (45V 36p + heat). Each experimental group was tested after
injection of the respective plasmid concentration and volume. Gene expression levels were
measured 2, 5, 7, 9, and 14 days after gene delivery via in vivo bioluminescence imaging.
Statistical analysis
Statistical significance between groups for the luciferase reporter gene experiment was
determined using a 2-way analysis of variance (ANOVA) with a Tukey-Kramer multiple
comparisons posttest. Results are expressed as the mean of 5-8 replicates per group (± SEM).
Significant results were determined with respect to animals receiving injection of plasmid DNA
alone unless otherwise noted. A P value less than 0.05 was considered significant.
Statistical significance between groups for the reporter gene dosing experiment was
determined using a 2-way analysis of variance (ANOVA) with a Tukey-Kramer multiple
comparisons post-test (GraphPad Prism Software, La Jolla, California). Results are expressed as
the mean of 4-8 replicates per group (± SEM). Significant results were determined with respect
to animals receiving injection of plasmid DNA alone unless otherwise noted. A P value less than
0.05 was considered significant.
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RESULTS
Moderate heat-assisted GET yields sustained expression levels compared to unheated
counterpart
Moderate heat-assisted GET was demonstrated in a guinea pig model using the reporter
gene firefly luciferase as a preliminary tool to test gene delivery in the skin. The luciferase
expression pattern following the application of various pulsing parameters with and without
the addition of moderate heat was recorded over a two-week observation period (Figure 10A).
Peak expression in vivo was observed 48 hours after exposure in all tested conditions. The
highest level of expression, 3.66x108 photons/second (p/s), was achieved with 45V 36 pulses
plus moderate heat at this time point (p<0.05). Furthermore, this same condition yielded the
highest expression levels at both observation days 5 and 7 with a gradual decline over the 14day observation period (p<0.01). Results indicate that the pulse number and applied voltage
could be reduced by 50% (72 to 36 pulses) and 23% (45V to 35V) respectively, with the addition
of moderate heating via infrared laser to achieve the same expression levels.
We also determined the effect of reducing the number of active optical fibers for
applying moderate heat to the target. As described, the infrared laser-heating component is
distributed equally among nine optical fibers that are arranged equidistant in spans of three
across three rows. They can be blocked individually or by row, therefore allowing for sharp
control of the thermal distribution. We tested the efficacy of moderate heat row by row in
combination with our highest performing GET condition- 45V 36 pulses.

There was no

significant difference between applying moderate heat with 3, 6, or 9 optical fibers in our
aforementioned highest expressing GET protocol (Figure 10B).
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Figure 10. Expression kinetics of moderate heat-assisted GET to the skin. (A) Experimental
groups included injection only (IO) plus heat (IO+heat), injection of pDNA followed by 72 pulses

39

at 45V (45V 72p) or 35V (35V 72p), 72 pulses at 35V with moderate heat (35V 72p + heat), and
36 pulses at 45V with (45V 36p + heat) or without heating (45V 36p). (B) Flexibility and
distribution of heating was assessed for 3, 6, and 9 active optical fibers followed by GET at 45V
36p. Luciferase expression levels reported as average total flux (photons/second) ± SEM, n=8
individual sites per group. *, p<0.05, **, p<0.01.

Gene expression following moderate heat-assisted GET extended to the dermis and
underlying muscle
To determine the distribution and localization of gene delivery following moderate heatassisted gene electrotransfer, fluorescence staining was performed. The reporter gene,
gWizLuc-myc-DDK, was delivered to guinea pig skin via intradermal injection with or without
GET and moderate heat (Figure 11). No expression was observed following an intradermal
injection with moderate heat alone (Figure 11A). Immunohistochemical evaluation
demonstrated that expression was localized in the dermis and muscle layer of the tissue in
those animals receiving moderate heat-assisted GET (Figure 11F-G). The addition of moderate
heat resulted in a higher level of expression at the reduced 35V compared to the same
condition treated at room temperature (Figure 11B-C). When GET was combined with
moderate heat using half the amount of pulses, 36 (Figure 11F-G) versus 72 (Figure 11D-E), this
expression pattern was more pronounced suggesting a long-lasting effect.

40

41

Figure 11. Distribution of expression following moderate heat-assisted GET to the skin. An
indirect fluorescence staining protocol using an anti-DDK primary antibody and secondary
antibody, Alexa Fluor 488, was performed on guinea pig skin fixed in 4% PFA 48 hours after
GET. Samples were paraffin embedded and sections were counterstained with DAPI. Images are
representative of 3-4 individual subjects. Experimental groups included (A) injection only plus
heat (IO+heat), (B,C) injection of pDNA followed by 72 pulses at 35V at ambient (35V 72p) or
after the application of moderate heating (35V 72p +heat), (D,E) 72 pulses at 45V (45V 72p)
applied at ambient, and (F,G) 36 pulses at 45V after the application of moderate heat from an
infrared laser (45V 36p + heat). (A-D, F) 100x, scale bar =100μm. (E,G) 200x, scale bar = 50μm.

Moderate heating mitigates a reduction in pulse number and skin damage caused by high
voltage GET
Histological analysis was performed to assess tissue damage after the application of GET
(Figure 12). H&E staining on fixed tissue sections revealed that the application of a higher pulse
number at a higher applied electric field resulted in a burn extending from the epidermis to the
hypodermis with infiltrating cells suggesting injury (Figure 12A, C). When moderate heating was
applied at the same electric field at 50% of the pulsing dose, histological damage was not
observed (Figure 12B, D).
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Figure 12. Histological analysis after cutaneous moderate heat-assisted GET. H&E staining was
performed on guinea pig skin fixed in 4% PFA and paraffin embedded. Images are
representative of 3-4 individual subjects. Experimental groups included (A) injection of pDNA
followed by 72 pulses at 45V (45V 72 p no heat) and (B) 36 pulses at 45V after the application of
moderate heat from an infrared laser (45V 36p + heat). 40x, scale bar = 500μm. (C) Cell
infiltrate visible at site of damage following 45V 72 pulses, 200x, scale bar = 10μm. (D) Intact
tissue with no apparent damage after 45V 36p + heat, 200x, scale bar = 10μm.
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Increasing the volume of plasmid DNA and not the concentration yielded highest expression
levels
Plasmid DNA dosing was optimized by varying both the concentration and intradermal
injection volume at each delivery site. For this work, the reporter gene luciferase was used to
determine the kinetics of luciferase expression following the application of various pulsing
parameters with and without the addition of moderate heat. Two volumes: 50 and 100μL and
three concentrations: 0.5, 1, and 2mg/mL were evaluated across four experimental conditions
including injection only, moderately heated GET conditions of 36 pulses at 45V and 72 pulses at
35V, and ambient GET conditions of 72 pulses at 45V.
Peak luciferase expression in vivo was observed 48 hours after exposure in all tested
parameters and decreased gradually over the two-week period of observation (Figure 13). A
100μL injection at 1mg/mL yielded the highest overall level of luciferase expression in all tested
parameters compared to all other concentrations and volumes. The highest expression was
shown in those animals receiving 36 pulses at 45V with a total flux of 9.9x108 ± 1.8x108
photons/sec after just two days (Figure 13C). These results were significant compared to
injection of plasmid DNA alone (p<0.001) (Figure 13A). Similarly, 72 pulses at 45V delivered at
ambient temperature following a 100μL injection at 1mg/mL resulted in a total flux of 8.84x108
± 5.66x108 photons/sec (Figure 13D). However, this condition served as a positive control, in
that although expression levels were high, the superficial damage attributed to these GET
parameters were unfavorable and negated its potential use for translation.
In the high-pulse, low-voltage moderately heated GET condition (35V 72p +heat), the
highest expression level was also observed at day 2 with a total flux of 2.38x108 ± 2.82x107
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photons/sec after a 100μL injection at 1mg/mL (Figure 13B). Though at a peak level lower than
that of the other tested GET conditions, these results were significant with respect to those
animals receiving injection of plasmid DNA alone of the same volume and concentration
(p<0.01). Though not significant, on observation days 7 and 9, animals receiving the higher
plasmid DNA concentration of 2mg/mL in an injection volume of 100μL followed by 35V 72
pulses plus moderate heating, displayed a trend of elevated expression levels compared to the
other five dosing parameters at the same time point.
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Figure 13. Optimization of plasmid DNA dosing for moderate heat-assisted GET to the skin.
Experimental groups included (A) injection pDNA only (IO), (B) 72 pulses at 35V with moderate
heat (35V 72p + heat), injection of pDNA followed by GET with (C) 36 pulses at 45V with
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moderate heating (45V 36p + heat) or (D) 72 pulses at 45V without moderate heating (45V 72
p). Plasmid DNA doses included volumes of 50 or 100μL at 0.5, 1, or 2mg/mL. Luciferase
expression levels reported as average total flux (photons/second), n=5-8 individual sites per
group.

DISCUSSION
There are a number of associated effects of thermal application to consider including
pain sensation, skin discoloration, inhibition of cellular processes, and injury. In the current
work, we present a platform for reversible electroporation in the skin, where cell viability is
maintained. We heat the skin to a moderate temperature of 43°C for a total of 30 seconds and
maintain an elevated temperature for an additional 20 seconds after the exogenous heat
source is removed. Our previous work in an ex vivo pig skin model and in a 3D human skin
model, suggested that moderate heating via an infrared laser provided fast, uniform heating of
the target. At this temperature, the skin is temporarily warm and normal metabolism still
proceeds. We observed no injury to the skin after moderate heat was applied in vivo.
Conversely, high voltages and pulse number led to skin damage both macroscopically and
microscopically. We observed this effect by way of reddened skin and confirmed through H&E,
in animals receiving 45V and 72 pulses without moderate heat, suggesting that although this
condition yielded a high level of expression, it was damaging and not ideal for translation for
non-life-threatening applications. The combination of moderate heating and GET allowed for a
significant reduction in both pulse number (50%) and applied electric field (23%) all while
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achieving similar, or even higher overall luciferase expression levels in some cases. Moreover,
tissue damage was not observed in reduced GET conditions with moderate heating. These are
promising features of moderate heat-assisted GET, providing a shorter, less painful delivery
platform compared to high voltage-high pulse GET performed at ambient. The result is a faster,
minimally invasive route of electrotransfer.
We observed expression in the lower dermis and muscle following moderate heatassisted GET. These data are encouraging as the propensity for a deliverable to reach systemic
circulation is higher in these tissues. Furthermore, our data demonstrate that an intradermal
approach can yield expression in the muscle using a non-penetrating electrode with the
addition of moderate heating. The enhanced membrane fluidity associated with temperature
increases could explain this phenomenon. Interestingly, we observed little expression in the
epidermis, the local site of delivery, suggesting the plasmid DNA is electrophoretically pushed
by both the applied electric field and the application of moderate heat.
Lastly, we sought to optimize the volume and concentration of plasmid to achieve the
highest level of transgene expression. We found that a 100μL injection at 1mg/mL achieved the
highest level of luciferase expression when followed by 45V 36 pulses with moderate heating.
This is likely attributed to better coverage of the plasmid DNA injection by the applied electric
field and exogenous moderate heating source, given that a 100μL injection measures
approximately 8mm, while a 50μL spans approximately 5mm. Taken together these results
prompted future studies on the utility of moderate heat-assisted GET using therapeutic agents.
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CHAPTER IV
MODERATE HEAT-ASSISTED GET FOR INTRADERMAL DNA VACCINCATION AGAINST HEPATITIS
B VIRUS
INTRODUCTION
Hepatitis B virus (HBV) is a leading global cause of liver disease (83-86). HBV infection is
endemic in Asia, the Pacific Islands, Eastern Europe, and Sub-Saharan Africa where most of the
population are carriers (87-89). The virus is transmitted via blood or sexual contact and is quite
resilient, able to survive outside the body for up to seven days. Each year there are
approximately 200,000 new HBV cases in the US (90). The symptoms of HBV infection are nonspecific and infection is generally confirmed through blood laboratory analysis once latent
indications appear. Preventative HBV vaccination has reduced the disease burden; however, an
estimated 350 million people worldwide are living with chronic HBV (91).
Vaccination schedule compliance is critical for HBV prevention. Current guidelines
recommend beginning vaccine dosing within 24 hours of birth, followed by two to three
additional doses within the first year of life (92,93). Global vaccination estimates of children are
unclear on the extent to which vaccines are administered completely and on time. In practice,
vaccines tend to be given later rather than earlier. When HBV vaccination is delayed, children
fail to receive adequate protection when they are most vulnerable. Late vaccinations raise the
risk of HBV infection by lengthening the period of susceptibility. This can have important
implications in countries where HBV infection is endemic, increasing the probability of
transmission. In this situation, catch-up vaccination of older children has relatively little impact
for prophylaxis because infection may already have been acquired by the time they present for
vaccination. Vaccine compliance in endemic regions is related to access barriers. Limited
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facilities, inadequately funded vaccination programs, means and distance of travel to clinics,
storage logistics and capacity all hinder immunization coverage. The current recommended HBV
vaccine is recombinant protein consisting of the viral envelope protein Hepatitis B surface
antigen and requires strict cold storage to maintain its stability (83,90-92).
DNA vaccines are an attractive alternative to standard vaccine types, given their
innocuous make-up and simplicity of production requirements, however there are several
pitfalls. Previous DNA vaccines in the clinical pipeline have demonstrated poor cellular uptake
and immunogenicity rendering them inconsistent or ineffective for conferring protection. These
shortcomings can be mediated through enhanced delivery protocols beyond the standard
needle-fitted syringe administration. Delivery of plasmid encoding viral antigen through GET
has potential as a DNA vaccination platform (38,40,94-97). A recent preclinical study delivering
a DNA vaccine via GET showed HBV-specific T-cell responses in humans (97,98).
Here we present moderate heat-assisted GET as a novel vaccine delivery platform
utilizing a combination of moderate heating and non-invasive electrotransfer via the MEA. We
have previously shown the advantages of combining electrotransfer with moderate heating
where both pulse number and applied voltage could be significantly reduced resulting in a
shorter and less painful method (37,78). Futhermore, using the MEA for intradermal delivery
has been shown to be both effective and tolerable (39,78,80,81,99). Minimizing discomfort is
an important consideration for translation to non-life-threatening applications such as
vaccination, in which schedule compliance is critical to achieve immunization coverage. Here
we present moderate heat-assisted GET for the delivery of a DNA vaccine against HBV. To
evaluate this method, we utilized a guinea pig model for delivery of a DNA vaccine encoding
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Hepatitis B surface antigen. The objective of this work was to determine the appropriate
moderate heat-assisted GET parameters for achieving elevated Hepatitis B surface antibodies in
circulation with the overarching goal of conferring humoral immunity against HBV.
MATERIALS AND METHODS
Animals
Animals used for the HBV vaccination study were 8-10-week-old Female Hartley guinea
pigs weighing approximately 300-350g at the time of treatment. The animals were housed at
the Old Dominion University animal facility and procedures approved by the Old Dominion
Institutional Animal Care and Use Committee approval #17-022. All animal subjects were
quarantined for a minimum of 7 days following arrival and prior to the conduction of any
procedures.
Animal euthanasia was performed at the conclusion of the 30-week observation period.
This procedure was previously described in Chapter III and was performed in the same manner
for this study. Briefly, Euthanasia was carried out by first anesthetizing the animals in a
chamber filled with 4% isoflurane combined with 96% oxygen. After 15 minutes, the animals
were transferred to a separate chamber and euthanized by exposure to carbon dioxide for 15
minutes. Compressed gas was used as the carbon dioxide source. The chamber was not prefilled, but slowly filled, and cleaned and dried between animal groups. A bilateral thoracotomy
was performed to confirm euthanasia. This secondary euthanasia procedure was only
performed after cessation of respiratory and cardiovascular movements was confirmed.
Euthanasia procedure were approved by the IACUC at ODU and followed in accordance.
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Infrared Laser system for moderate heating
For moderate heat application, the electrode was placed with the spring-loaded GET
electrode pins in contact with the skin, leaving a fixed distance of 1cm between the optical
fibers and the vaccine target. The laser was applied for a total of 30 seconds following injection
of plasmid DNA. This duration allowed for 43°C to be maintained for 30 seconds after removal
of the moderate heating source. The GET protocol was approximately 20 seconds in duration,
enabling the tissue to remain heated during its application. Moderate heating was always
applied prior to and never concurrently with GET. Safety precautions such as eyewear and
barriers were in place during all laser operations. All staff were trained and received operation
approval via the Radiation & Laser Safety Program at Old Dominion University prior to the
conduction of any experiments.
GET operating parameters
The moderate heating and GET delivery was incased in a single device. The design of the
MEA GET delivery device has been previously described (80,81,99). Briefly, the electrode has 16
pins arranged in a 4x4 pattern at 2-mm-apart. Each pair of electrodes was programmed to
administer either a train of four pulses with total 72 pulses or two pulses for a total of 36 pulses
depending on pulsing conditions. The applied voltage was either 35 or 45 V between two
conductive pins, each with a pulse duration of 150 ms and a 150 ms delay between pulses.
Electrotransfer was performed using the UltraVolt Model: Rack-2-500-00230 (UltraVolt, Inc.
Ronkonkoma, NY, USA).
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Plasmids
For the HBV vaccination study, endotoxin-free plasmid encoding Hepatitis B surface
antigen (gWizHBsAg) was professionally prepared and suspended to 2 mg/mL in 0.9% sterile
injectable saline (Aldevron). The plasmid has a gWiz backbone and a pCMV promoter.
Moderate heat-assisted GET delivery of pHBsAg
Female guinea pigs weighing approximately 350 g were used for this study as they
represent a model for human skin. Anesthesia was performed as previously described. After
animals were sufficiently anesthetized, they were fitted with a standard rodent mask supplied
with 3% isofluorane and 97% oxygen to maintain a surgical plane of anesthesia. The right flank
was shaved and washed in the same aforementioned fashion, ensuring the removal of
sebaceous oils prior to GET. Moderate heat-assisted GET was applied after the preoperative
cleansing procedure. The five tested groups included: IO + heat (injection of plasmid without
GET and with moderate heating), pHBsAg+45V 36p (plasmid with high-voltage low-pulse GET),
pHBsAg+45V 36p+heat (plasmid with moderate heating and high-voltage low-pulse GET),
pHBsAg+35V 72p (plasmid with moderate heating and low-voltage high-pulse GET) and
pHBsAg+45V 72p (plasmid with high-voltage high-pulse GET). pHBsAg was injected at a single
site intradermally in a 100 µL volume at a concentration of 1mg/mL (100 µg total) immediately
before moderate heating via infrared laser or GET application. Operating parameters for both
moderate heating and GET were delivered as previously described. After primary vaccination,
each animal was monitored continuously until they recovered from anesthesia, as indicated by
their ability to maintain sternal recumbency and exhibit purposeful movement. Boost
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vaccinations were administered 14 days after the prime protocol in appropriate subjects in the
same manner, except on a different location on the animal’s flank.
HBsAg neutralizing antibody production
An ELISA kit specific for guinea pig anti-HBsAg (KA0286, Novus Biologicals) was used to
detect anti-HBs in all animal subjects. Sera was collected via a jugular vein puncture and
isolated in serum separator tubes, which were then assayed per the manufacturer’s
instructions. Serum was collected 6, 11, 18, 24, and 30 weeks after immunization. Sera
collected prior to vaccination was used to determine baseline levels of circulating anti-HBs. Two
standard deviations from the mean of this baseline served as a positive result. Serial dilutions
were performed on the serum samples to accommodate these criteria. The results are reported
as HBsAb Geometric Mean Titer.
Statistical Analysis
Statistical significance between the groups for HBV DNA vaccination was determined by
2-way ANOVA with a Tukey-Kramer multiple comparisons post-test (GraphPad Prism Software,
La Jolla, California). Results are expressed as the mean of 5 individuals per group (± SEM).
A P value less than 0.05 was considered significant.
RESULTS
Moderate heat-assisted and ambient GET induces the production of antibodies against HBV
surface antigen following intradermal injection of pHBsAg
Circulating antibodies specific to HBV surface antigen have been shown to be efficacious
for conferring HBV humoral immunity. Surveillance of HBsAb titer is used clinically to determine
if a follow-up boost vaccination is warranted, as a drop in levels of this antibody suggests a drop
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in immunization protection. The ability of moderate heat-assisted GET to induce the production
of HBsAbs after injection of a plasmid encoding HBV surface antigen was tested by comparing
the levels of antibody titers in the serum to unheated GET conditions. All GET parameters had
been previously tested for gene expression in the dosing optimization experiment. Based on
results from the dosing experiment, an intradermal injection of 100μL at 1mg/mL was used for
this work. GET parameters for DNA vaccination against HBV included: injection only plus
moderate heating, 45V 36 pulses with and without moderate heating, 35V 72 pulses plus
moderate heating, and 45V 72 pulses without moderate heating. Guinea pigs were injected
with pHBsAg followed by appropriate GET and/or moderate heating conditions. A boost
vaccination was given in the same manner after 2 weeks at a different site than the prime.
Serum collected via the jugular vein over a 30-week observation period was assayed using an
ELISA.
Overall, HBsAb titers induced by DNA vaccination with pHBsAg via all GET parameters,
moderately heated or ambient, were significantly higher than an injection only control with
moderate heating. All GET groups displayed a steady increase in antibody production, peaking
at week 18 and gradually waning out to the end of the 30-week observation period. Notably,
45V 36 pulses with moderate heating yielded significantly higher HBsAb titers compared to all
other tested conditions at all observation time points (p<0.001) (Figure 14). By week 18, HBsAb
titers in this condition (45V 36p +heat) peaked and were 230-fold higher than those in an
injection only control with moderate heating (IO +heat) (p<0.001). Furthermore, antibody
production at week 18 in the experimental condition 45V 36 pulses with moderate heating
were 20-fold over the HBsAb titer achieved by its ambient counterpart (45V 36p) (p<0.01).
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Though the plasmid dosing experiment carried out with the luciferase reporter gene
indicated that expression levels following GET with 45V 72 pulses were similar to 45V 36 pulses
plus moderate heating, we did not observe such similarities in HBsAb antibody production
between these two treatments. Specifically, at peak antibody production, 45V 36 pulses with
moderate heating was still nearly 10-fold higher than the levels achieved with 45V 72 pulses
delivered at ambient temperature (p<0.01).

Figure 14. HBsAb production induced by moderate heat-assisted GET after a prime-boost DNA
vaccination protocol against HBV. Prime and boost vaccinations were separated by two weeks.
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All animals received an intradermal injection of a plasmid encoding Hepatitis B surface antigen
(pHBsAg) in a 100μL volume at 1mg/mL. Experimental groups included injection pDNA only plus
moderate heating (IO+heat), injection of pDNA followed by GET with 72 pulses at 45V (45V 72
p), 72 pulses at 35V with moderate heat (35V 72p + heat), and 36 pulses at 45V with (45V 36p +
heat) or without moderate heating (45V 36p). Serum was collected via jugular vein puncture 6,
11, 18, 24, and 30 weeks after immunization. Serum collected prior to vaccination was used to
determine baseline levels of circulating HBsAbs. HBsAb titer in serum was measured by an
ELISA. Two standard deviations from the mean of this baseline served as a positive result. Serial
dilutions were performed on the serum samples to accommodate these criteria. The results are
reported as HBsAb Geometric Mean Titer ± SEM, n=5 individuals per group. *, p<0.05,

**,

p<0.01, ***, p<0.001,.

Moderate heat-assisted GET elicits significantly higher HBsAbs after both prime and boost
vaccination schedules
HBV DNA vaccination was evaluated after a single primary dose to determine HBsAg
antibody production at a reduced schedule. For this work, we assessed efficacy of the four
previously tested GET groups: 35V 72 pulses with moderate heating, 45V 72 pulses, and 45V 36
pulses with and without moderate heating. After the prime vaccination protocol, peak antibody
production was observed at week 6 across all tested GET parameters. Just as we observed after
the boost vaccination, HBsAb titers in those animals receiving pHBsAg followed by the high-
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voltage low-pulse moderately heated condition (45V 36p +heat), were significantly higher than
all other GET conditions (Figure 15). At week 6, HBsAb titers were 3-fold higher in the
experimental condition 45V 36 pulses with moderate heating compared to its ambient
counterpart (45V 36p) (p<0.05). Similarly, this condition was 1.73 and 2.5-fold higher than 45V
72 pulses without moderate heating and 35V 72 pulses plus moderate heating respectively.
Overall, antibody production from the prime protocol was far lower than those levels
achieved from two doses: a prime and boost given two weeks apart. However, though a lower
level of antibody production was observed, the same trends between the tested GET
parameters were replicated in this experiment where 45V 36 pulses plus moderate heat
induced the highest overall level of HBsAb production.
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Figure 15. HBsAb production induced by moderate heat-assisted GET after a prime only DNA
vaccination protocol against HBV. No boost vaccination was administered in this experiment. All
animals received an intradermal injection of a plasmid encoding Hepatitis B surface antigen
(pHBsAg) in a 100μL volume at 1mg/mL. Experimental injection of pDNA followed by GET with
72 pulses at 45V (45V 72 p), 72 pulses at 35V with moderate heat (35V 72p + heat), and 36
pulses at 45V with (45V 36p + heat) or without moderate heating (45V 36p). Serum was
collected via jugular vein puncture 6, 11, 18, 24, and 30 weeks after immunization. Serum
collected prior to vaccination was used to determine baseline levels of circulating HBsAbs.
HBsAb titer in serum was measured by ELISA. Two standard deviations from the mean of this
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baseline served as a positive result. Serial dilutions were performed on the serum samples to
accommodate these criteria. The results are reported as HBsAb Geometric Mean Titer ± SEM,
n=5 individuals per group. *, p<0.05.

DISCUSSION
Whole-pathogen and subunit vaccines predominate current vaccine schedules (100).
Whole-pathogen vaccines contain either killed or live-attenuated or weakened strains that
cannot cause disease, but are able to elicit an immune response. Subunit vaccines are
comprised of only the essential antigens of a particular pathogen along with adjuvants to
achieve long-term immunity, as antigen alone is often not enough to confer protection. Though
effective, these formulations require strict cold storage to maintain stability, are costly to
manufacture, require multiple scheduled doses to achieve life-long protection, and can have
serious side effects in some recipients, such as those with allergies or compromised immune
systems, and in rare cases can lead to reversion to a disease-causing state (100-102).
DNA vaccines consist of a plasmid that carries genes encoding proteins from the
pathogen of interest (95-97). When delivered, the plasmid enters host cells and serves as a
genetic template for the translation of its antigen. DNA vaccines are non-live and nonreplicating, leaving little risk for secondary infection from vaccination. Due to well-established
production protocols, DNA plasmid vaccines can be made rapidly, shortening the time between
an outbreak and the public health response. This streamlined approach is advantageous with
the emergence of new pathogens. DNA vaccines are an ideal global vaccination candidate due
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to their robust temperature stability, specificity to target antigen, and ease of large-scale
manufacturing. These advantages make DNA vaccines an inexpensive option and therefore
more feasible in low-income regions where access to the general population is a barrier
(100,103,104).
Reversible electroporation, where the cells survive, is largely considered a nonthermal
process. GET falls under this category where a high voltage pulse is applied creating transient
permeations in the cell membrane that are resealed once the pulse is removed (105). Physical
methods of GET are used both in vitro and in vivo and are well tolerated in living tissues
(11,15,16,37,40,80). By adding moderate heating to this approach, there is an increase in
membrane fluidity allowing for the widening of the transient permeations already caused by
GET (76,106,107). Thus, the interaction of moderate heating and GET affords both a reduction
in the necessary pulse number and applied voltage to achieve a similar or enhanced result
(37,78). In practice, moderate heat-assisted GET provides a faster and less painful delivery
platform with all the same benefits as ambient GET.
In the current work, we evaluated the use of moderate heat-assisted GET for the
delivery of a DNA vaccine against HBV. Our initial testing to confirm plasmid dosing allowed for
more prudence in determining the proper volume and concentration of plasmid to deliver in
our vaccination study. We found that a 100μL injection at 1mg/mL achieved the highest level of
luciferase expression when followed by 45V 36 pulses with moderate heating. This is likely
attributed to better coverage of the plasmid DNA injection by the applied electric field and
exogenous moderate heating source, given that a 100μL injection measures approximately
8mm, while a 50μL spans approximately 5mm. Previous studies using reporter genes have
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determined that a total concentration of 100μg achieved the highest expression levels
(37,39,78,80,82). Our results are in line with these data.
In all of our experiments we chose to use 45V 72 pulses as a positive control, which in
our experience is a MEA condition that reliably induces high expression levels. However, we
hypothesized this high-voltage high-pulse condition would not be suitable for translation due to
observable skin damage caused from its application. On this basis, we sought to reduce either
the pulse number and/or the applied voltage with the addition of moderate heat to
compensate for expression loses all while maintaining tissue health. Tissue health is critical for
reversible electroporation approaches such as GET, where live cells are needed to achieve gene
expression in the host. Furthermore, in non-life-threatening applications such as vaccination
visible scarring and pain at the delivery site are unappealing side effects. These could be
overlooked in some cases, where the benefit outweighs the detriment of the side effect, but it
is not ideal. We found that with the addition of moderate heat, we were able to reduce the
applied voltage by 23% and the pulse number by 50% all while achieving a similar luciferase
expression level and eliminating the tissue damaging side effects.
For the delivery of a DNA vaccine against HBV, we evaluated both a prime and a prime
plus boost vaccination protocol. We found that GET parameters of 45V 36 pulses with the
addition of moderate heat far exceeded the serum levels of HBsAbs produced by any of the
other GET conditions we tested in both the prime and prime plus boost vaccination protocols.
These levels were especially elevated in those animals receiving the prime plus boost
vaccination schedule and remained stable during the entire 30-week observation period. This
suggests that the effects of moderate heat-assisted GET with respect to antibody production
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are long lasting. Vaccine longevity is just as critical as compliance, so these results are
encouraging. Furthermore, all of the GET conditions we evaluated induced significant HBsAb
production compared to injection of pHBsAg alone. Interestingly, though the high-voltage highpulse condition (45V 72p) showed similar expression levels in our reporter gene experiment,
this did not translate to high antibody production in our vaccination study. This could imply that
the tissue damage and effects induced by these delivery parameters is too severe to achieve a
robust antibody response.
The results of the prime vaccination protocol followed the same trend as the prime plus
boost protocol, just at a far lower magnitude. We still observed that GET parameters of 45V 36
pulses with moderate heating induced the highest level of HBsAb production compared to the
other tested GET conditions. These results suggest that prime vaccination alone can prompt
enduring antibody production in this case, though the prime plus boost protocol was far more
robust and more likely to confer long lasting protection. These data were important to collect,
as vaccine schedule compliance is a concern among both patients and physicians. An effective
vaccine capable of producing sustained protective antibody titers could eliminate the need for
multiple booster vaccinations, an appealing solution for all parties. The current vaccination
schedule for HBV in infants recommends a series of 3 shots: shortly after birth, aged 1-2
months, and 6-18 months (86,92,93).
Moderate heating increased the overall expression levels achieved by intradermal GET
applied at ambient temperature. Moreover, using moderate heat allows for greater penetration
depth for the applied electric fields, creating a situation where the uptake of plasmid DNA by
professional antigen presenting cells such as dendritic cells is more likely (108-110). This is an
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essential aspect of an effective vaccine, mediated by both the cellular and humoral immune
systems and dependent upon the specificity for the plasmid-encoded antigen (103,108-111).
Where we have historically viewed an intradermal delivery platform as confined to the
epidermis and dermis, with the addition of moderate heating it could be possible for aqueous
delivery via cutaneous GET to the hypodermis and muscle tissues. This expression pattern was
previously demonstrated using reporter genes. The long-lasting HBsAg antibody production we
observed after DNA vaccination in our moderately heated GET condition (45V 36p +heat) is
evidence that muscle delivery with an intradermal approach is not only possible, but also more
than likely occurring. This is favorable, as most vaccines require muscle delivery, though it is
unclear if their administration is precise as muscle is an underlying unseen tissue that is not so
easily monitored. In addition, intramuscular vaccinations typically administered in the deltoid
muscle can cause upper arm injury, bursitis, or other shoulder dysfunctions if not carefully
administered (112-115). In infants, intramuscular vaccinations are given in the vastus lateralis
located in anterolateral thigh. This site has been deemed the safest intramuscular route,
though the middle of the muscle should be the target, not the upper or lower portion, as its
adjacency to the muscle branch of the femoral nerve and the lateral circumflex femoral artery
(115-117). Intradermal delivery by contrast is visible and therefore easier to ensure correct
administration. With moderate heat-assisted GET there are the advantages of muscle delivery
with an intradermal approach.
We have previously shown the utility the MEA device for DNA vaccination with a
plasmid encoding protective antigen against B. anthracis in a murine model as well as for
delivering the same plasmid administered in this work against HBV (40,118). Here we expand
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upon this original platform and present moderate heat-assisted GET as a novel method with a
reconfigured device for intradermal DNA vaccination. Our preliminary results demonstrate that
moderate heat-assisted GET yields a significantly higher and longer duration of expression
compared to needle-fitted syringe injection alone in vivo. As a proof of principle, we show
enduring antibody production against HBV in vivo over a period of 30 weeks following
moderate heat-assisted GET. Compared to our original work, adding moderate heat to GET
induced antibody production nearly 8-fold over GET using the MEA at ambient temperature
(118). These results indicate the synergy between moderate heat and GET to enhance gene
delivery in the skin. Future work should involve characterizing the cellular immune response
induced by this approach and a challenge experiment to confirm its protective effects against
HBV. Also, these results warrant the consideration of additional vaccinations utilizing plasmidencoded antigens delivered via moderate heat-assisted GET.
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CHAPTER V
MODERATE HEAT-ASSISTED GET FOR PROTEIN REPLACEMENT THERAPY IN THE SKIN
INTRODUCTION
A number of clinical trials have shown positive results for gene-based therapies
(119,120). Expression of the delivered gene must be controlled in order to achieve an effective
therapeutic outcome while minimizing toxicity and other adverse effects. Though effective,
cutaneous GET requires elevated electric fields to penetrate the stratum corneum. A minimally
invasive method that does not require the use of high electric fields would facilitate delivery
with minimal local discomfort and could potentially reduce or eliminate visible scaring.
To enhance the translatability of GET it is imperative to modify the approach in a
manner that could use lower applied voltage while maintaining expression and thereby
reducing potential tissue damage. The second issue is to be able to achieve delivery in a
minimally invasive manner to the deep- or sub-dermis. One concept to achieve this is to reduce
the distance between electrodes. We have previously shown the efficacy a non-invasive MEA
for gene electrotransfer to the skin that utilizes a short gap between electrodes
(36,80,81,107,118). While this approach improved the outcome with respect to reduced tissue
damage, expression was still confined to the epidermis (80). Therefore, alternative strategies
were explored to further improve tissue effect as well as to achieve deeper penetration. GET is
generally considered a nonthermal process wherein a high voltage pulse is applied creating
transient passage through the cell membrane for extracellular deliverables. However, the
application of moderate heat can enhance cell membrane fluidity. We therefore, explored the
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combination of gene electrotransfer and moderate heating and demonstrated that this could
be used to enhance gene delivery to cells and tissues.
While increased temperature can enhance delivery when used together with GET, it is
also important to moderate the applied heat so as not to cause tissue damage. It is well
established that thermal injury is determined by temperature and duration such that as the
temperature is increased, the less time it takes to cause burning or tissue damage (29). We
previously established that the optimal intradermal temperature for enhancing GET was 43°C
(78). The synergy of this moderate heating protocol and GET resulted in a shorter, lower voltage
treatment, presumably more tolerable than a high-voltage high-pulse number approach.
Minimizing discomfort is an important consideration for translation of cutaneous deliveries
where multiple applications may be necessary such as protein replacement therapy.
Factor IX is a critical clotting protein present in human plasma. Patients suffering from
Hemophilia B are variably deficient in the content or activity of this protein, and must receive
repeated scheduled injections or intravenous Factor IX to survive. We previously demonstrated
the non-invasive delivery of Factor IX using the MEA, where the bulk expression was confined
to the skin with a small portion reaching systemic circulation (39). We thus evaluated if using
moderate heating as an adjuvant to non-invasive GET may yield higher or more sustained
Factor IX protein expression.
The current work demonstrates the utility of moderate heat-assisted GET to the skin
using a novel application device based on the design of the MEA. With this device, the addition
of an exogenous heating component allows for enhanced uniformity in thermal distribution
across the target by way of nine optical fibers connected to an infrared laser. This combination
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platform was tested for cutaneous delivery of a therapeutic protein, human Factor IX. The aim
of this work was to determine if moderate heat-assisted GET resulted in the expressed protein
reaching the blood circulation and for how long this expression was maintained.
For this reason, we suggested the use of moderate heat-assisted GET for delivery of
human clotting factor IX. Factor IX is a plasma protein that is critical for thrombosis. Hemophilia
B is an X-chromosome linked genetic bleeding disorder in which patients are variably deficient
in Factor IX, with ranges below the normal 50-100% plasma protein content (121). It affects
approximately one in 30,00 live births and 20% of all Hemophiliacs. Current therapy for
Hemophilia B requires frequent dosages administered via injection or central line. These
formulations are either recombinant protein or plasma-derived product and have short halflives. Plasmid DNA by contrast to the aforementioned platforms is self-stable, inexpensive to
produce, and innocuous. In the last five years there have been viral gene therapy clinical trials
using rAAV to deliver Factor IX (121-123). Though there has been some success in showing
extended therapeutic benefit, use of this therapy in patients such as children, those with preexisting immunity to AAV, and those with hepatitis have been excluded. To mediate this,
transient immune suppression or a gain of function Factor IX variants have been suggested to
alleviate the unintended side effects from using an AAV vector (68,75,124). For these reasons
non-viral alternatives should be considered. Moreover, a minimally invasive route of
administration to the skin rather than to the liver, the natural site of Factor IX production,
would be ideal in this clinical situation where the risk of severe bleeding is a real concern.
The high expression levels potentiate the use of moderate heat-assisted GET for protein
replacement therapy. Sustained protein expression is critical for the treatment of conditions
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such as Hemophilia B, where less frequent visits and administrations are not only economical,
but also life saving. We demonstrated that moderate heat-assisted GET yielded a significantly
higher and longer duration of expression compared to needle-fitted syringe injection alone. In
addition, both the pulse number and voltage were reduced by 50% and 23% respectively with
the addition of moderate heat, thereby minimizing the perceived pain and superficial damage.
Expression was localized in the dermis and muscle layers, thus permitting the ability of
therapeutic proteins to reach systemic circulation where they can be most effective.
MATERIALS AND METHODS
Animals
The in vivo model for this work was the same as was used in the previous in vivo studies
presented in Chapters III and IV, as guinea pig skin is similar in both composition and thickness
to human skin. Animals used for this study were 8-10-week-old Female Hartley guinea pigs
weighing approximately 300-350g at time of procedures. Animal weights were monitored
weekly. The animals were housed at the Old Dominion University animal facility and procedures
approved by the Old Dominion Institutional Animal Care and Use Committee. IACUC protocol
number 17-022 at ODU was followed in accordance for all procedures. All animal subjects were
quarantined for a minimum of 7 days following their arrival and prior to the conduction of any
experimental procedures.
Plasmids
Endotoxin-free plasmid prepared at 2mg/mL in 0.9% sterile injectable saline of human
factor IX expression vector, pNGVL3-CMV-hFIXm1 (generous gift by Dr. Kurachi) was
commercially prepared (Aldevron, Fargo, ND). This plasmid operates under a CMV promoter.
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Infrared laser heat application
Animals were anesthetized with O2 containing 2.5-3.0% isoflurane. Prior to treatment
both flanks were shaved and washed with mild soap and water to remove loose hair and
cleanse the skin of any abundance of oil. This washing procedure was previously described in
Chapters III and IV. Moderate heating via a Class IV Laser power supply (LaserMate Group, Inc)
via a laser optic fiber (Model: M79L005 Thor Labs Inc.) was applied immediately following a
50μL 2mg/mL intradermal injection of plasmid DNA to the pre-washed and shaven flank skin for
a total duration of 30 seconds, after which the laser was switched off. All safety precautions
were adhered to while the laser was in operation, including eye protection and barriers.
Electrode design
A novel applicator was constructed that enabled the administration of moderate
heating and electric pulses. An infrared radiation emitter was integrated into the applicator.
The emitter consists of an optical fiber whose beam is split equally among 9 individual optical
fibers utilizing 4 splitter boxes. Main optical fiber is directly connected to a 3-way splitter box,
which had three fibers that each wet to another 3-way splitter box. Those nine fibers were then
incorporated into the MEA (Figure 3). These fibers are positioned equidistant and centrally
between 16 0.5mm gold-plated round tipped pins each spaced 2mm apart, creating a combined
6 by 6 mm moderate heating electrode array (Figure 3). As previously shown, the small size and
dielectric material of the optical fiber can be integrated into a GET delivery system. The optical
fiber was connected to an infrared semiconductor laser, providing up to 8W of irradiative
power at a wavelength of approximately 900 nm. The design of the electrode was modeled
after the MEA, delivering 150ms pulses applied in pairs perpendicularly where 4 of 16
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electrodes are active at one given time [74]. Following this pulsing pattern, a total of 18 pulses
are thereby delivered per round.
Factor IX gene delivery
Animals were anesthetized with O2 containing 2.5-3.0% isoflurane. As previously
described in the other moderate heat-assisted GET studies, animals were pre-shaven and
washed with mild soap and water to remove any loose hair or an overabundance of oil. Two
100μg intradermal injections of plasmid DNA encoding human Factor IX were given on separate
targets on the same flank. The electrode array was immediately positioned over the injection
area with or without exogenous moderate heating. For these studies both 2 and 4 rounds of 18
150ms pulses were delivered, yielding a total of 36 and 72 pulses respectively. In addition,
applied voltages of 35V and 45V were assessed. Each site was injected, heated, and pulsed
separately and each animal received only one pulsing condition with or without the application
of moderate heat. As a positive control group, an intramuscular injection to the hind limb was
delivered followed by application of penetrating needle electrodes delivering pulses at 100V/M
[119].
Factor IX gene delivery to multiple sites was carried out by prepping the animal subjects
in the same way, with skin pre-shaven and washed whilst under a surgical plane of anesthesia.
Multiple application sites were given in sets of 2, 3, or 4 100 μg intradermal injections of
plasmid DNA encoding human Factor IX. All sites were injected individually, immediately heated
then pulsed with 36 pulses at 45V before proceeding to another site. Sites were evenly spaced
along the same flank with 1.5 cm distance between each individual site. All sites received the
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same heating and pulsing conditions in this experiment where the scalability of Factor IX
delivery was evaluated.
Factor IX protein expression analysis
Blood from treated guinea pigs was collected via jugular vein puncture on days 2, 7, 14,
21, 35, 63, and 100. All collections were performed while animals were anesthetized with
O2 containing 2.5-3.0% isoflurane. Animals were monitored until recovery from anesthesia as
evidenced by the ability to maintain sternal recumbency. Blood was allowed to clot for at least
one hour at room temperature in serum separator tubes. Serum was carefully collected and
used to measure clotting factor IX content via a Human Factor IX ELISA kit (ab188393, Abcam).
Statistical analysis
Statistical significance between the groups for the delivery of human Factor IX was
determined by 2-way ANOVA with a Tukey-Kramer multiple comparisons test (GraphPad Prism
Software, La Jolla, California). Results are expressed as the mean of 5 individuals per group (±
SEM). A P value less than 0.05 was considered significant.
RESULTS
Factor IX is expressed systemically following moderate heat-assisted GET to the skin
To assess the efficacy of moderate heat-assisted GET for cutaneous delivery of a
therapeutic protein, human Factor IX was delivered via this platform in a guinea pig model.
Serum was collected from animals following GET. Systemic Factor IX content was reported over
a period of 100 days (Figure 16). Moderate heat-assisted GET (45V 36p +heat) yielded the
highest protein levels nearing 10ng/mL two weeks after delivery, at least 2- fold over any other
treatment condition. Expression waned for this condition and dropped completely by day 35.
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The other intradermal conditions, moderately heated or not, followed a similar protein
expression pattern, though not at such a high level as the latter. We included an intramuscular
GET (IM 100V/cm) condition to serve as a positive control for Factor IX delivery. Conversely to
the intradermal GET results, Factor IX protein levels following intramuscular delivery
experienced an initial lag and peaked at 8.43ng/mL ± 0.50 at 35 days (p<0.01). This increased
level of expression was sustained for another two months up to 100 days, ending the
observation period.
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Figure 16. Factor IX expression following moderate heat-assisted and intramuscular GET.
Human Factor IX in guinea pig serum. Experimental groups included two intradermal injections
of pDNA followed by 72 pulses at 45V (45V 72p), 72 pulses at 35V with moderate heat (35V 72p
+ heat), 36 pulses at 45V with moderate heating (45V 36p + heat), and a single intramuscular
injection of pDNA followed by 8 pulses at 100V/cm. The data represent the average ± SEM, n=5
individuals per group. *,p<0.05, **,p,0.01.

Multiple site applications enhance Factor IX protein levels
The scalability of cutaneous delivery of human Factor IX via moderate heat-assisted GET
was evaluated. Moderate heat-assisted GET was applied in sets of 2, 3, or 4 separate site doses
on the same flank in respective animal subjects. Serum was collected from the animals
following treatment. Systemic Factor IX protein levels were recorded over a period of 100 days
(Figure 17). Utilizing our highest expressing delivery condition from the previous experiment,
45V 36p +heat, we carried out multiple site applications. We observed the highest expression
levels nearing 10 ng/mL between 2-3 weeks after delivery across all three experimental groups.
Factor IX protein levels then began to wane. The most pronounced drop was in those animals
receiving just two application sites, while those receiving 3 or 4 sites maintained elevated
Factor IX protein levels for longer. Factor IX protein levels in those animals receiving 3
application sites was significant with respect to those receiving just 2 sites at day 63 (p<0.05).
Furthermore, in those animals receiving 4 moderate-heat assisted GET application sites, Factor
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IX protein levels in the serum were significantly elevated at days 63 and 100 compared to
application of 2 sites (p<0.05, p<0.01).

Figure 17. Scalability of Factor IX delivery via moderate heat-assisted GET. Human Factor IX in
guinea pig serum. Experimental groups included two, three, or four intradermal injections of
pDNA encoding human Factor IX followed by 36 pulses at 45V with moderate heating (45V 36p
+ heat). The data represent the average ± SEM, n=5 individuals per group. *,p<0.05, **,p,0.01.
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DISCUSSION
The results from Chapter III highlight the high expression levels achieved with the use of
moderate heat-assisted GET for the delivery of reporter genes. Here we suggest this platform
for protein replacement therapy. Elevated and long-lived protein expression is critical for the
treatment of conditions such as Hemophilia B, where less frequent visits mean fewer injections
or infusions carrying a lower risk of severe bleeding. In Chapter III, we demonstrated that
moderate heat-assisted GET yielded a significantly higher and longer duration of expression
compared to needle-fitted syringe injection alone, where both the pulse number and voltage
were reduced by 50% and 23% respectively with the addition of moderate heating. Expression
distribution was localized in the dermis and muscle layers, which we surmise would be
advantageous for applications such as Factor IX protein replacement therapy, for achieving
sustained protein expression levels.
We included an intramuscular GET delivery dose in our Factor IX experiment as a
positive control since this platform has been shown to yield long-term sustained transgene
expression (125-127). We observed just that in our study, with Factor IX protein levels peaking
35 days after IM GET delivery and waning gradually out to 100 days of continued observation.
At day 35, expression among all intradermal delivery groups dropped. In comparing this pattern
to our intradermal GET delivery, peak expression was observed 14 days following moderate
heat-assisted GET at 45V 72 pulses, where expression levels after IM GET were 2.5-fold lower at
this same time point (p <0.05).
While these results are very promising, we do recognize that actual protein levels are
still low. Normal physiological level of Factor IX is 100ng/mL, so adjustments would need to be
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made to increase the amount of protein that actually reaches circulation, otherwise this could
only be useful for patients suffering from mild Hemophilia B, where Factor IX levels are greater
than 5% but less than 50% total plasma protein content. We addressed this concern by
evaluating the scalability of moderate heat-assisted GET for Factor IX delivery. In this case, we
selected our highest expressing GET condition (45V 36p +heat) and tested the effects of
additional sites on Factor IX protein levels in the serum. We observed peak protein levels in all
experimental groups of 2, 3, and 4 injection sites within 21 days after initial delivery. Like our
initial experiment, protein expression dropped sharply after peaking in those animals receiving
just two application sites. Interestingly, protein levels remained significantly elevated in animals
receiving 3 or 4 moderate heat-assisted GET application sites with prolonged Factor IX
expression up to 100 days after delivery. This is encouraging and suggests the potential to scale
up to enhance the amount of protein that reaches systemic circulation. Beyond simply adding
more injection sites, modifications to increase the delivery surface area could be achieved by
designing a larger applicator. Moreover, alternative therapeutic purposes where smaller
amounts or weight of product are needed, such as growth hormone delivery, could also be an
appropriate application for this technology (128,129).
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CHAPTER VI
CONCLUSIONS
In this study we evaluated the use of a novel device performing moderate heat-assisted
GET for intradermal delivery in two applications: DNA vaccination and protein replacement
therapy. Optimization of the infrared laser as the exogenous moderate heating source was
carried out in an ex vivo pig skin model as well as a 3D human skin model before in vivo studies
were performed. The guinea pig was used as the animal model for these studies. In vivo
moderate heating parameters were defined as the application of heat for 30 seconds to reach
an intradermal temperature of 43°C, which was maintained for approximately 20 seconds after
the removal of the exogenous heating source.
Delivery of reporter genes via moderate heat-assisted GET was tested before moving to
therapeutic agents to assess ideal parameters for achieving high expression levels. We found
that a high-voltage low-pulse number condition plus moderate heating (45V 36p +heat)
resulted in a significant increase in luciferase expression compared to any of the other tested
conditions. These results were similar to a positive control condition, high-voltage high-pulse
number (45V 72p), which displayed burning at the treatment site and therefore deemed
unsuitable for translation to non-life-threatening applications. Conversely, despite displaying
high expression levels, no skin damage was observed in the moderately heated condition.
Expression distribution was found to extend to the deep dermis and muscle of those animals
receiving high-voltage low-pulse number GET with the addition of moderate heat. This
suggested that an intradermal approach could result in muscle gene delivery and precipitated
efforts to demonstrate its efficacy in therapeutic applications.

78

We evaluated the utility of moderate heat-assisted GET for the delivery of a DNA
vaccine against HBV. We previously found that a plasmid dose of 100μL at 1mg/mL induced the
highest reporter gene expression, so this dose was utilized for the DNA vaccination study. A
plasmid encoding Hepatitis B surface antigen was given in a prime-boost and prime only
vaccination protocol. Our data indicate that neutralizing antibodies to HBsAg were elevated in
serum 230-fold over injection of plasmid DNA alone in those animals receiving our highest
expressing condition (45V 36p +heat). Antibody titers peaked 18 weeks after a prime-boost
vaccination protocol and remained elevated over all other tested conditions for the duration of
the 30-week observation period. We did not observe this high level of HBsAb in our highvoltage high-pulse positive control condition (45V 72p), suggesting the damage observed with
this condition was too severe to generate a robust antibody response. Due to the high
generation of antibodies following the prime-boost protocol, we evaluated antibody generation
with this platform using a prime only protocol. Vaccine compliance is a concern, so the
advantage of a single dose vaccination compared to a boost protocol is less vaccinations, which
may be an easier recommendation to follow. In our prime only protocol, we found that
antibody titers were generated in all of our GET conditions, with the moderately heated highvoltage low-pulse number condition (45V 36p +heat) being the highest for the duration of the
30-week observation period. Antibody titers were still much lower in this case compared to the
prime-boost protocol, suggesting the later to be more effective at conferring immunity.
Finally, we evaluated the efficacy of moderate heat-assisted GET for the delivery of
human Factor IX to the skin. Like our previous in vivo studies, a guinea pig model was used for
this work. Here we show that systemic Factor IX protein generation was induced following our
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moderately heated high-voltage low-pulse number GET condition (45V 36P +heat). These levels
peaked at 14 days near 10ng/mL, ten-fold below therapeutic levels. We included an
intramuscular GET delivery condition as a positive control. Factor IX expression peaked at 35
days following GET as the intradermal GET conditions were waning. Taken together this is
encouraging, suggesting the utility of a two-armed delivery approach using both IM GET and
moderate heat-assisted GET, to achieve both the early Factor IX expression with moderate
heat-assisted GET and the lagged but sustained levels achieved with IM GET. While these
results are very promising, we do recognize that actual protein levels are still low. Normal
physiological level of Factor IX is 100ng/mL, therefore adjustments would need to be made to
increase the amount of protein that actually reaches circulation. To accomplish this, we scaled
up our delivery approach by evaluating overall Factor IX delivery using multiple delivery sites.
These data suggest the platform is scalable, and therefore updates to the electrode
configuration could further enhance the utility of this technology. An infrared laser was chosen
as the heating source in this case due to its speed and precision at which the target
temperature could be reached and specifically applied. However, in the future, utilizing
different albeit slower exogenous heating sources such as LED, induction, or convection could
be advantageous towards creating a more user-friendly platform in general.
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